Navigation Links
SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services

Bound Brook, NJ (PRWEB) July 24, 2014

As part of the long-term strategic approach, DZS expects to manage numerous projects in the MENA region during 2014 with potential global expansion.

"We are delighted to have a preferred provider agreement with DZS to manage our clinical trials globally and in particular in the MENA region,” said Global VP of R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh Rehani. "DZS has developed excellent operational practices with a focus on utilizing eClinical software and flexible team structures that allow companies to reduce development costs yet maintain high quality services and meet timelines. This helps pharma companies to meet the many challenges of drug development."

“We are pleased to be able to partner with SBI at a strategic level. Our Sponsors are increasingly looking for innovative approaches to bring products to market effectively and efficiently,” said Greg Ambra, VP of Clinical Operations. “Our flexible project team models, collaborative approach, and proprietary eClinical Software, ClinPlus®, increases the level of collaboration and allows us to respond quickly to our Sponsor’s needs, while maintaining our focus on high quality deliverables.”

About DZS Clinical Services:
DZS Clinical Services is a full-service Contract Research Organization providing clinical trial services and eClinical software for the biotech and pharmaceutical industry. DZS Clinical Services is a division of DZS Software Solutions, Inc., a privately held company founded in 1984. Over 60 clients globally use DZS services and software for trial monitoring and management, data capture, data cleaning, analysis, and reporting. When ClinPlus® software is coupled with DZS services and training, clients have dramatically improved productivity and maximized the value of R&D investments by obtaining fast, high-quality results leading to better decisions.

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
2. Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
3. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
4. Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
5. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
6. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
7. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
8. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
9. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
10. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
11. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):